B-Cell Lymphoma Treatments

Find B-Cell Lymphoma Treatments

Brand Name

Columvi

Generic Name

Glofitamab

View Brand Information

FDA approval date: June 15, 2023

Classification: Bispecific CD20-directed CD3 T Cell Engager

Form: Concentrate, Solution

What is Columvi (Glofitamab)?

COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (1.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Feasibility Study of Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma

Enrollment Status: Recruiting

Publish Date: October 28, 2026

Intervention Type: Procedure, Biological, Drug, Other

Study Phase: Phase 1

Summary: This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific monoclonal antibody, which can bind to two different antigens that are expressed by cancer cells (CD3 an...

Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Enrollment Status: Recruiting

Publish Date: October 26, 2026

Intervention Type: Procedure, Biological, Drug

Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Venetoclax is in a class of medications called B-cell lymphoma-2 ...

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Enrollment Status: Recruiting

Publish Date: October 23, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

View All Clinical Trials

Related Latest Advances

The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

Journal: Blood advances

Published: August 19, 2026

View All Latest Advances

Brand Information

Columvi (Glofitamab)

WARNING: CYTOKINE RELEASE SYNDROME

Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS. Withhold COLUMVI until CRS resolves or permanently discontinue based on severity [see .

1INDICATIONS AND USAGE

COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and durability of response

2DOSAGE FORMS AND STRENGTHS

Injection:

2.5 mg/2.5 mL (1 mg/mL) clear, colorless solution in a single-dose vial.
10 mg/10 mL (1 mg/mL) clear, colorless solution in a single-dose vial.

3CONTRAINDICATIONS

None.

4ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Cytokine Release Syndrome
Neurologic Toxicity
Serious Infections
Tumor Flare

4.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

5DRUG INTERACTIONS

For certain CYP substrates where minimal concentration changes may lead to serious adverse reactions, monitor for toxicities or drug concentrations of such CYP substrates when coadministered with COLUMVI.

Glofitamab-gxbm causes the release of cytokines

6DESCRIPTION

Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager. It is a recombinant humanized anti-CD20 anti-CD3ɛ bispecific immunoglobulin G1 (IgG1) monoclonal antibody produced in Chinese hamster ovary (CHO) cells. Glofitamab-gxbm has an approximate molecular weight of 197 kDa.

COLUMVI (glofitamab-gxbm) injection is a sterile, preservative-free, colorless, clear solution supplied in single-dose vials for intravenous infusion.

COLUMVI is supplied in 2.5 mg/2.5 mL and 10 mg/10 mL single-dose vials at a concentration of 1 mg/mL. Each mL of solution contains 1 mg glofitamab-gxbm, histidine (0.63 mg), histidine hydrochloride monohydrate (3.34 mg), methionine (1.49 mg), polysorbate 20 (0.5 mg), sucrose (82.15 mg), and Water for Injection, USP, at pH 5.5.

7HOW SUPPLIED/STORAGE AND HANDLING

COLUMVI (glofitamab-gxbm) injection is a sterile, preservative-free, colorless, clear solution for intravenous infusion.

COLUMVI is supplied as:

8PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (

9PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton

NDC 50242-127-01

Columvi

(glofitamab-gxbm)

10 mg/10 mL

For Intravenous Infusion

Single-Dose Vial.

ATTENTION: Dispense the enclosed

1 vial

Rx only

11038205

PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton

10PRINCIPAL DISPLAY PANEL - 2.5 mg/2.5 mL Vial Carton

NDC 50242-125-01

Columvi

(glofitamab-gxbm)

2.5 mg/2.5 mL

For Intravenous Infusion

Single-Dose Vial.

ATTENTION: Dispense the enclosed

1 vial

Rx only

11038250

PRINCIPAL DISPLAY PANEL - 2.5 mg/2.5 mL Vial Carton